Lumbosacral Radicular Pain Management Global Market Report 2025

The lumbosacral radicular pain management market size has grown strongly in recent years. It will grow from $0.85 billion in 2024 to $0.9 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the increasing prevalence of lumbar disc herniation, heightened awareness of spinal disorders, a growing elderly population, advancements in diagnostic imaging technologies, and the broader adoption of non-invasive pain management therapies.

The lumbosacral radicular pain management market size is expected to see strong growth in the next few years. It will grow to $1.11 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period can be attributed to innovations in minimally invasive surgical techniques, the rising adoption of biologic therapies, an increasing emphasis on personalized pain management, growing demand for outpatient pain clinics, and the integration of digital health and telemedicine into pain management practices. Key trends expected during this period include progress in minimally invasive spine surgeries, advancements in neurostimulation devices, the use of biologic therapies such as platelet-rich plasma, the application of AI-driven diagnostics and personalized treatment strategies, and the development of new non-opioid analgesics.

The increasing prevalence of back pain disorders is expected to drive the growth of the lumbosacral radicular pain management market in the coming years. Back pain disorders encompass various conditions affecting the spine, muscles, or nerves in the back, resulting in discomfort or pain. This rise is largely attributed to sedentary lifestyles that weaken back muscles, leading to poor posture and chronic pain. Lumbosacral radicular pain management focuses on alleviating nerve root irritation in the lower back, thereby reducing pain and inflammation, restoring mobility, and enhancing overall quality of life. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that in 2022, more than half (52%) of hospitalizations for back problems were due to back or spinal pain, with lower back pain accounting for the highest proportion at 27%, followed by neck pain at 6.2% and radiculopathy at 6%. Additionally, back problems had become the third leading contributor to the total health burden in 2023, representing 4.3% of the overall impact. As a result, the growing prevalence of back pain disorders is a key factor fueling the expansion of the lumbosacral radicular pain management market.

Leading companies in the lumbosacral radicular pain management market are concentrating on developing advanced therapies, such as investigational oral NaV1.8 pain signal inhibitors, to provide non-opioid options for long-lasting pain relief. These investigational drugs target the NaV1.8 sodium channel, a critical component in transmitting pain signals through sensory nerves. For example, in December 2024, Vertex Pharmaceuticals, a U.S.-based biotechnology company, released results from its Phase 2 clinical trial of suzetrigine for treating painful lumbosacral radiculopathy (LSR). The trial achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in pain from baseline in patients receiving suzetrigine. The drug was generally well tolerated, with no serious adverse events reported. Vertex plans to address the high placebo response observed in the study in upcoming Phase 3 trials to better evaluate the drug’s efficacy.

In October 2024, Stryker Corporation, a U.S.-based medical technology company, acquired Vertos Medical Inc. for an undisclosed amount. Through this acquisition, Stryker seeks to expand its interventional pain management portfolio, increase its footprint in ambulatory surgery centers, and enhance its capabilities in minimally invasive treatments for chronic lower back pain. Vertos Medical Inc. is a U.S.-based company specializing in interventional pain management solutions, particularly the minimally invasive mild® procedure for treating lumbar spinal stenosis.

Major players in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

North America was the largest region in the lumbosacral radicular pain management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lumbosacral radicular pain management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lumbosacral radicular pain management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lumbosacral radicular pain management involves a comprehensive strategy for diagnosing, treating, and alleviating pain caused by irritation or compression of the spinal nerve roots in the lumbosacral region (lower back and sacral area). This condition is often linked to issues such as herniated discs, spinal stenosis, or degenerative disc disease. Treatment focuses on reducing inflammation, relieving pressure on the affected nerves, and supporting functional recovery. The primary goal is to improve mobility, reduce pain, and enhance the patient’s overall quality of life.

The key categories of medications used in managing lumbosacral radicular pain include non-steroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, anticonvulsants, and steroids. NSAIDs are commonly used as a first-line treatment to alleviate pain and inflammation by blocking the enzymes responsible for inflammation. Management may also involve various physical therapies, including manual therapy, exercise therapy, electrotherapy, thermal therapy, and hydrotherapy. These treatments are delivered through different routes, such as oral and topical administration, and are made available through multiple distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The lumbosacral radicular pain management market research report is one of a series of new reports that provides lumbosacral radicular pain management market statistics, including the lumbosacral radicular pain management industry global market size, regional shares, competitors with the lumbosacral radicular pain management market share, detailed lumbosacral radicular pain management market segments, market trends, opportunities, and any further data you may need to thrive in the lumbosacral radicular pain management industry. This lumbosacral radicular pain management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lumbosacral radicular pain management market consists of revenues earned by entities by providing services such as psychological therapy, surgical intervention, chiropractic care, and pharmacological management. The market value includes the value of related goods sold by the service provider or included within the service offering. The lumbosacral radicular pain management market includes sales of muscle relaxants, epidural steroid injections, and nerve blocks. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.